Vitamin D3 insufficiency and colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 594-612

  Di Rosa, Michelino ^a   Malaguarnera, Michele ^a   Zanghì, Antonio ^a   Passaniti, Antonino ^b   Malaguarnera, Lucia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic activity; Colorectal cancer; Vitamin D3

Indexed keywords

BETA CATENIN; CALCITRIOL; COLECALCIFEROL; DICKKOPF 1 PROTEIN; GLUCURONOSYLTRANSFERASE; KALLIKREIN 6; MICRORNA 22; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; SPROUTY PROTEIN; TRANSCRIPTION FACTOR RUNX; UVOMORULIN; VANILLOID RECEPTOR 6; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOAVAILABILITY; CALCIUM HOMEOSTASIS; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DICKKOPF GENE; DNA REPAIR; ENZYME REGULATION; EXPERIMENTAL STUDY; GENE TARGETING; HUMAN; IMMUNE FUNCTION TEST; INFLAMMATION; MEMBRANE DAMAGE; NONHUMAN; OBSERVATIONAL STUDY; PHOSPHATE METABOLISM; RECEPTOR DOWN REGULATION; REVIEW; VITAMIN D DEFICIENCY;

ANTINEOPLASTIC ACTIVITY; COLORECTAL CANCER; VITAMIN D3;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CHOLECALCIFEROL; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIGENE FAMILY; OSTEOPONTIN; RECEPTORS, CALCITRIOL; STEROID HYDROXYLASES; VITAMIN D DEFICIENCY;

EID: 84888290376     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.016     Document Type: Review

References (152)

1. Holick M.F. Vitamin D: a millennium perspective. Journal of Cellular Biochemistry 2003, 88:296-307.
2. Norman A.W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006, 147:5542-5548.
3. Di Rosa M., Malaguarnera M., Nicoletti F., Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology 2011, 134:123-139.
4. Di Rosa M., Malaguarnera G., De Gregorio C., Palumbo M., Nunnari G., Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cellular Immunology 2012, 280:36-43.
5. Wang Y., Zhu J., DeLuca H.F. Where is the vitamin D receptor?. Archives of Biochemistry and Biophysics 2012, 523:123-133.
6. Matusiak D., Murillo G., Carroll R.E., Mehta R.G., Benya R.V. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiology, Biomarkers & Prevention 2005, 14:2370-2376.
7. Holick M.F., Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. The American Journal of Clinical Nutrition 2008, 87:1080S-1086S.
8. González-Sancho J.M., Larriba M.J., Ordóñez-Morán P., Pálmer H.G., Muñoz A. Effects of 1alpha, 25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Research 2006, 26:2669-2681.
9. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer 2007, 7:684-700.
10. Peltomäki P. Mutations and epimutations in the origin of cancer. Experimental Cell Research 2012, 318:299-310.
11. Donehower L.A., Creighton C.J., Schultz N., Shinbrot E., Chang K., Gunaratne P.H., et al. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. Journal of Pathology 2013, 229:99-110.
12. Mishra J., Drummond J., Quazi S.H., Karanki S.S., Shaw J.J., Chen B., et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Critical Reviews in Oncology/Hematology 2013, 86:232-250.
13. Grant W.B. Role of solar UVB irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries. Dermatoendocrinology 2012, 4:203-211.
14. Zhang X., Giovannucci E. Calcium, vitamin D and colorectal cancer chemoprevention. Best Practice & Research Clinical Gastroenterology 2011, 25:485-494.
15. Woolcott C.G., Wilkens L.R., Nomura A.M., Horst R.L., Goodman M.T., Murphy S.P., et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiology, Biomarkers & Prevention 2010, 19:130-134.
16. Freedman D.M., Looker A.C., Abnet C.C., Linet M.S., Graubard B.I. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Research 2010, 70:8587-8597.
17. Cheng J.B., Levine M.A., Bell N.H., Mangelsdorf D.J., Russell D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:7711-7715.
18. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocrine Reviews 2008, 29:726-776.
19. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results in Cancer Research 2003, 164:29-42.
20. Torchia J., Glass C., Rosenfeld M.G. Co-activators and co-repressors in the integration of transcriptional responses. Current Opinion in Cell Biology 1998, 10:373-383.
21. Meyer M.B., Goetsch P.D., Pike J.W. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1α,25-dihydroxyvitamin D3. Journal of Biological Chemistry 2010, 285:15599-15610.
22. Demay M.B., Kiernan M.S., DeLuca H.F., Kronenberg H.M. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:8097-8101.
23. Gurlek A., Pittelkow M.R., Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha, 25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocrine Reviews 2002, 23:763-786.
24. Rowling M.J., Kemmis C.M., Taffany D.A., Welsh J. Megalin mediated endocytosis of vitamin D-binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. Journal of Nutrition 2006, 36:2754-2759.
25. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiology, Biomarkers & Prevention 2002, 11:113-119.
26. Cross H.S., Nittke T., Kallay E. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Molecular and Cellular Endocrinology 2011, 347:70-79.
27. Lechner D., Kallay E., Cross H.S. 1α,25-Dihydroxyvitamin D(3) down-regulates CYP27B1 and induces CYP24A1 in colon cells. Molecular and Cellular Endocrinology 2007, 263:55-64.
28. Cross H.S., Bareis P., Hofer H., Bischof M.G., Bajna E., Kriwanek S., et al. 25-Hydroxyvitamin D(3)-1alphahydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66:287-292.
29. Risio M., Lipkin M., Newmark H., Yang K., Rossini F.P., Steele V.E., et al. Apoptosis, cell replication, and Western-style diet-induced tumorigenesis in mouse colon. Cancer Research 1996, 56:4910-4916.
30. Newmark H.L., Lipkin M., Maheshwari N. Colonic hyperplasia and hyperproliferation induced by a nutritional stress diet with four components of Western-style diet. Journal of the National Cancer Institute 1990, 82:491-496.
31. Xue L., Lipkin M., Newmark H., Wang J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. Journal of the National Cancer Institute 1999, 91:176-181.
32. Reddy B.S. Diet and excretion of bile acids. Cancer Research 1981, 41:3766-3768.
33. Nagengast F.M., Grubben M.J., van Munster I.P. Role of bile acids in colorectal carcinogenesis. European Journal of Cancer 1995, 31A:1067-1070.
34. Peterlik M., Cross H.S. Vitamin D and calcium deficits predispose for multiple chronic diseases. European Journal of Clinical Investigation 2005, 35:290-304.
35. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
36. Nehring J.A., Zierold C., DeLuca H.F. Lithocholic acid can carry out in vivo functions of vitamin D. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:10006-10009.
37. Han S., Li T., Ellis E., Strom S., Chiang J.Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Molecular Endocrinology 2010, 24:1151-1164.
38. Kawaura A., Tanida N., Sawada K., Oda M., Shimoyama T. Supplemental administration of 1 alpha-hydroxyvitamin D3 inhibits promotion by intrarectal instillation of lithocholic acid in N-methyl-+-N-nitrosourea-induced colonic tumorigenesis in rats. Carcinogenesis 1989, 10:647-649.
39. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha, 25-dihydroxy vitamin D3. Molecular Pharmacology 2001, 60:1399-1406.
40. McCarthy T.C., Li X., Sinal C.J. Vitamin D receptor dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. Journal of Biological Chemistry 2005, 280:23232-23242.
41. Ordóñez-Morán P., Larriba M.J., Pendás-Franco N., Aguilera O., González-Sancho J.M., Muñoz A. Vitamin D and cancer: an update of in vitro and in vivo data. Frontiers in Bioscience 2005, 10:2723-2749.
42. Scaglione-Sewell B.A., Bissonnette M., Skarosi S., Abraham C., Brasitus T.A. A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21 Waf1, and p27 Kip1. Endocrinology 2000, 141:3931-3939.
43. Lin R., Wang T.T., Miller W.H., White J.H. Inhibition of F-Box protein p45 SKP2 expression and stabilization of cyclindependent kinase inhibitor p27 KIP1 in vitamin D analog-treated cancer cells. Endocrinology 2003, 144:749-753.
44. Tong W.M., Hofer H., Ellinger A., Peterlik M., Cross H.S. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncology Research 1999, 11:77-84.
45. Sheinin Y., Kaserer K., Wrba F., Wenzl E., Kriwanek S., Peterlik M., et al. In situ mRNA hybridization analysis and immunolocalization of the vitamin D receptor in normal and carcinomatous human colonic mucosa: relation to epidermal growth factor receptor expression. Virchows Arch 2000, 437:501-507.
46. Oh Y.S., Kim E.J., Schaffer B.S., Kang Y.H., Binderup L., MacDonald R.G., et al. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Molecular and Cellular Endocrinology 2001, 183:141-149.
47. Lahm H., Amstad P., Wyniger J., Yilmaz A., Fischer J.R., Schreyer M., et al. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. International Journal of Cancer 1994, 58:452-459.
48. Polly P., Herdick M., Moehren U., Baniahmad A., Heinzel T., Carlberg C. VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB Journal 2000, 14:1455-1463.
49. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
50. 3. American Journal of Physiology - Gastrointestinal and Liver Physiology 2002, 283:G864-G874.
51. Manning A.M., Williams A.C., Game S.M., Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF-β): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene 1991, 6:1471-1476.
52. Kouchi Z., Fujiwara Y., Yamaguchi H., Nakamura Y., Fukami K. Phosphatidylinositol 5-phosphate 4-kinase type II beta is required for vitamin D receptor-dependent E-cadherin expression in SW480 cells. Biochemical and Biophysical Research Communications 2011, 408:523-529.
53. Gaschott T., Steinmeyer A., Steinhilber D., Stein J. ZK 156718, a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochemical and Biophysical Research Communications 2002, 290:504-509.
54. Harris D.M., Go V.L. Vitamin D and colon carcinogenesis. Journal of Nutrition 2004, 134(December (12 Suppl.)):3463S-3471S.
55. Díaz G.D., Paraskeva C., Thomas M.G., Binderup L., Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Research 2000, 60:2304-2312.
56. Barnes J.D., Arhel N.J., Lee S.S., Sharp A., Al-Okail M., Packham G., et al. Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis 2005, 10:301-311.
57. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
58. Gündüz M., Cacina C., Toptaş B., Yaylim-Eraltan I., Tekand Y., Isbir T. Association of vitamin D receptor gene polymorphisms with colon cancer. Genetic Testing and Molecular Biomarkers 2012, 16:1058-1061.
59. Bai Y.H., Lu H., Hong D., Lin C.C., Yu Z., Chen B.C. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World Journal of Gastroenterology 2012, 18:1672-1679.
60. Larriba M.J., Bonilla F., Muñoz A. The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression. Journal of Steroid Biochemistry and Molecular Biology 2010, 121:106-109.
61. Kallay E., Pietschmann P., Toyokuni S., Bajna E., Hahn P., Mazzucco K., et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001, 22:1429-1435.
62. Höbaus J., Fetahu I.S., Khorchide M., Manhardt T., Kallay E. Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells. Journal of Steroid Biochemistry and Molecular Biology 2012, (August).
63. Pálmer H.G., Larriba M.J., García J.M., Ordóñez-Morán P., Peña C., Peiró S., et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nature Medicine 2004, 10:917-919.
64. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation 2009, 119:1420-1428.
65. De Craene B., Gilbert B., Stove C., Bruyneel E., van Roy F., Berx G. The transcription factor SNAIL induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Research 2005, 65:6237-6244.
66. Larriba M.J., Valle N., Pálmer H.G., Ordóñez-Morán P., Alvarez-Díaz S., Becker K.F., et al. The inhibition of Wnt/beta-catenin signalling by 1alpha, 25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocrine-Related Cancer 2007, 14:141-151.
67. Peña C., García J.M., García V., Silva J., Domínguez G., Rodríguez R., et al. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. International Journal of Cancer 2006, 119:2098-2104.
68. Larriba M.J., Martín-Villar E., García J.M., Pereira F., Peña C., de Herreros A.G., et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 2009, 30:1459-1468.
69. Peña C., García J.M., Larriba M.J., Barderas R., Gómez I., Herrera M., et al. SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue. Oncogene 2009, 28:4375-4385.
70. Larriba M.J., Muñoz A. SNAIL vs. vitamin D receptor expression in colon cancer: therapeutics implications. British Journal of Cancer 2005, 92:985-989.
71. De Craene B., van Roy F., Berx G. Unraveling signalling cascades for the SNAIL family of transcription factors. Cell Signalling 2005, 17:535-537.
72. Bises G., Kállay E., Weiland T., Wrba F., Wenzl E., Bonner E., et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. Journal of Histochemistry & Cytochemistry 2004, 52:985-989.
73. Kim M.S., Fujiki R., Kitagawa H., Kato S. 1alpha, 25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Molecular and Cellular Endocrinology 2007, 265-266:168-173.
74. Dong L.M., Ulrich C.M., Hsu L., Duggan D.J., Benitez D.S., White E., et al. Vitamin D related genes. CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:2540-2548.
75. Horváth H.C., Khabir Z., Nittke T., Gruber S., Speer G., Manhardt T., et al. CYP24A1 splice variants - implications for the antitumorigenic actions of 1,25-(OH)2D3 in colorectal cancer. Journal of Steroid Biochemistry and Molecular Biology 2010, 121:76-79.
76. Norman A.W. 1α,25(OH) 2 - Vitamin D3mediated rapid and genomic responses are dependent upon critical structure function relationships for both the ligand and receptor(s). Vitamin D 2005, 381-387. Elsevier Academic Press, Burlington. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
77. Wood R.J., Tchack L., Angelo G., Pratt R.E., Sonna L.A. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiological Genomics 2004, 17:122-129.
78. 2 vitamin D3 on signal transduction systems in colonic cells. Steroids 1999, 64:137-142.
79. Aubin J.E., Heersche J.N.M. Vitamin D and osteoclast. Vitamin D. 2005, 649-663. Elsevier Academic Press, Burlington. D. Feldman, J.W. Pike, F.H. Glorieux (Eds.).
80. Ordóñez-Morán P., Alvarez-Díaz S., Valle N., Larriba M.J., Bonilla F., Muñoz A. The effects of 1,25-dihydroxyvitamin D3 on colon cancer cells depend on RhoA-ROCK-p38MAPK-MSK signaling. Journal of Steroid Biochemistry and Molecular Biology 2010, 121:355-361.
81. Pálmer H.G., González-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. Journal of Cell Biology 2001, 154:369-387.
82. Kim S., Shevde N.K., Pike J.W. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. Journal of Bone and Mineral Research 2005, 20:305-317.
83. Chang P.L., Lee T.F., Garretson K., Prince C.W. Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways. Clinical and Experimental Metastasis 1997, 15:580-592.
84. Kurisetty V.V., Johnston P.G., Johnston N., Erwin P., Crowe P., Fernig D.G., et al. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene 2008, 27:7139-7149.
85. Barletta F., Freedman L.P., Christakos S. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex. Molecular Endocrinology 2002, 16:301-314.
86. Xu H., McCann M., Zhang Z., Posner G.H., Bingham V., El-Tanani M., et al. Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Molecular Carcinogenesis 2009, 48:758-772.
87. Nemere I. 24,25-Dihydroxyvitamin D3 suppresses the rapid actions of 1,25-dihydroxyvitamin D3 and parathyroid hormone on calcium transport in chick intestine. Journal of Bone and Mineral Research 1999, 14:1543-1549.
88. Gumbiner B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996, 84:345-357.
89. Bezdekova M., Brychtova S., Sedlakova E., Langova K., Brychta T., Belej K. Analysis of snail-1, e-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. International Journal of Molecular Sciences 2012, 13:1632-1643.
90. Shah S., Islam M.N., Dakshanamurthy S., Rizvi I., Rao M., Herrell R., et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Molecular Cell 2006, 21:799-809.
91. Billin A.N., Thirlwell H., Ayer D.E. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Molecular and Cellular Biology 2000, 20:6882-6890.
92. Watson A.J. An overview of apoptosis and the prevention of colorectal cancer. Critical Reviews in Oncology/Hematology 2006, 57:107-121.
93. Halvey P.J., Zhang B., Coffey R.J., Liebler D.C., Slebos R.J. Proteomic consequences of a single gene mutation in a colorectal cancer model. Journal of Proteome Research 2012, 11:1184-1195.
94. Beildeck M.E., Islam M., Shah S., Welsh J., Byers S.W. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS ONE 2009, 4:e7872.
95. El-Tanani M.K., Barraclough R., Wilkinson M.C., Rudland P.S. Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4. Oncogene 2001, 20:1793-1797.
96. Gottardi C.J., Wong E., Gumbiner B.M. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. Journal of Cell Biology 2001, 153:1049-1060.
97. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
98. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Research 2009, 69:1343-1349.
99. Roberts D.M., Pronobis M.I., Poulton J.S., Waldmann J.D., Stephenson E.M., Hanna S., et al. Deconstructing the βcatenin destruction complex: mechanistic roles for the tumor suppressor APC in regulating Wnt signaling. Molecular Biology of the Cell 2011, 22:1845-1863.
100. Wong N.A., Pignatelli M. Beta-catenin - a linchpin in colorectal carcinogenesis?. The American Journal of Pathology 2002, 160(February (2)):389-401.
101. Kawasoe T., Furukawa Y., Daigo Y., Nishiwaki T., Ishiguro H., Fujita M., et al. Isolation and characterization of a novel human gene, DRCTNNB1A, the expression of which is down-regulated by beta-catenin. Cancer Research 2000, 60:3354-3358.
102. Cohen S.M., Chastain P.D., Rosson G.B., Groh B.S., Weissman B.E., Kaufman D.G., et al. BRG1 co-localizes with DNA replication factors and is required for efficient replication fork progression. Nucleic Acids Research 2010, 38:6906-6919.
103. González-Sancho J.M., Aguilera O., García J.M., Pendás-Franco N., Peña C., Cal S., et al. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 2005, 24(February (6)):1098-1103.
104. Aguilera O., Fraga M.F., Ballestar E., Paz M.F., Herranz M., Espada J., et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006, 25:4116-4121.
105. Aguilera O., Peña C., García J.M., Larriba M.J., Ordóñez-Morán P., Navarro D., et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 2007, 28(September (9)):1877-1884.
106. Pendás-Franco N., García J.M., Peña C., Valle N., Pálmer H.G., Heinäniemi M., et al. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha, 25-dihydroxyvitamin D3. Oncogene 2008, 27:4467-4477.
107. Mao B., Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003, 302:179-183.
108. You J., Nguyen A.V., Albers C.G., Lin F., Holcombe R.F. Wnt pathway-related gene expression in inflammatory bowel disease. Digestive Diseases and Sciences 2008, 53(April (4)):1013-1019.
109. Sato H., Suzuki H., Toyota M., Nojima M., Maruyama R., Sasaki S., et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007, 28:2459-2466.
110. Bazzi H., Fantauzzo K.A., Richardson G.D., Jahoda C.A., Christiano A.M. The Wnt inhibitor, Dickkopf 4, is induced by canonical Wnt signaling during ectodermal appendage morphogenesis. Developmental Biology 2007, 305:498-507.
111. Zitt M., Untergasser G., Amberger A., Moser P., Stadlmann S., Zitt M., et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Disease Markers 2008, 24:101-109.
112. Yu J., Tao Q., Cheng Y.Y., Lee K.Y., Ng S.S., Cheung K.F., et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009, 115:49-60.
113. Karin M., Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57:283-295.
114. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nature Cell Biology 2002, 4:E131-E136.
115. Buitrago C.G., Ronda A.C., de Boland A.R., Boland R. MAP kinases p38 and JNK are activated by the steroid hormone 1alpha, 25(OH)2-vitamin D3 in the C2C12 muscle cell line. Journal of Cellular Biochemistry 2006, 97:698-708.
116. Ward Y., Kelly K. Gem protein signaling and regulation. Methods in Enzymology 2006, 407:468-483.
117. Meyers M.B., Schneider K.A., Spengler B.A., Chang T.D., Biedler J.L. Sorcin (V19), a soluble acidic calcium-binding protein overproduced in multidrug-resistant cells. Identification of the protein by anti-sorcin antibody. Biochemical Pharmacology 1987, 36:2373-2380.
118. Wissenbach U., Niemeyer B.A. TRPV6. Handbook of Experimental Pharmacology 2007, 221-234. 179.
119. Meyer M.B., Watanuki M., Kim S., Shevde N.K., Pike J.W. The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Molecular Endocrinology 2006, 20:1447-1461.
120. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nature Reviews Cancer 2005, 5:376-387.
121. Bangsow C., Rubins N., Glusman G., Bernstein Y., Negreanu V., Goldenberg D., et al. The RUNX3 gene - sequence, structure and regulated expression. Gene 2001, 279:221-232.
122. Coffman J.A. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biology International 2003, 27:315-324.
123. Cameron E.R., Blyth K., Hanlon L., Kilbey A., Mackay N., Stewart M., et al. The Runx genes as dominant oncogenes. Blood Cells, Molecules and Diseases 2003, 30:194-200.
124. Marcellini S., Bruna C., Henríquez J.P., Albistur M., Reyes A.E., Barriga E.H., et al. Evolution of the interaction between Runx2 and VDR, two transcription factors involved in osteoblastogenesis. BMC Evolutionary Biology 2010, 10:78.
125. Underwood K.F., D'Souza D.R., Mochin-Peters M., Pierce A.D., Kommineni S., Choe M., et al. Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity. Journal of Bone and Mineral Research 2012, 27:913-925.
126. Emami N., Diamandis E.P. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Molecular Oncology 2007, 1:269-287.
127. Borgoño C.A., Michael I.P., Shaw J.L., Luo L.Y., Ghosh M.C., Soosaipillai A., et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. Journal of Biological Chemistry 2007, 282:2405-2422.
128. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Molecular Endocrinology 2002, 16:1243-1256.
129. Kutuzova G.D., De Luca H.F. 1,25-Dihydroxyvitamin D3 regulates genes responsible for detoxification in intestine. Toxicology and Applied Pharmacology 2007, 218:37-44.
130. Hashizume T., Xu Y., Mohutsky M.A., Alberts J., Hadden C., Kalhorn T.F., et al. Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha, 25-dihydroxyvitamin D3 conjugation. Biochemical Pharmacology 2008, 75:1240-1250.
131. Alvarez-Díaz S., Valle N., García J.M., Peña C., Freije J.M., Quesada V., et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. Journal of Clinical Investigation 2009, 119:2343-2358.
132. Cabrita M.A., Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008, 11:53-62.
133. Barbáchano A., Ordóñez-Morán P., García J.M., Sánchez A., Pereira F., Larriba M.J., et al. SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 2010, 29:4800-4813.
134. Agger K., Cloos P.A., Rudkjaer L., Williams K., Andersen G., Christensen J., et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes & Development 2009, 23:1171-1176.
135. Pereira F., Barbáchano A., Silva J., Bonilla F., Campbell M.J., Muñoz A., et al. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Human Molecular Genetics 2011, 20:4655-4665.
136. Alvarez-Díaz S., Valle N., Ferrer-Mayorga G., Lombardía L., Herrera M., Domínguez O., et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Human Molecular Genetics 2012, 21:2157-2165.
137. Meyer M.B., Goetsch P.D., Pike J.W. VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Molecular Endocrinology 2012, 26:37-51.
138. Méchin M.C., Coudane F., Adoue V., Arnaud J., Duplan H., Charveron M., et al. Deimination is regulated at multiple levels including auto-deimination of peptidylarginine deiminases. Cellular and Molecular Life Sciences 2010, 67:1491-1503.
139. Cristobo I., Larriba M.J., de los Ríos V., García F., Muñoz A., Casal J.I. Proteomic analysis of 1α,25-dihydroxyvitamin D3 action on human colon cancer cells reveals a link to splicing regulation. Journal of Proteomics 2011, 75:384-397.
140. Niv Y., Sperber A.D., Figer A., Igael D., Shany S., Fraser G., et al. In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma. Cancer 1999, 86:391-397.
141. Ahearn T.U., McCullough M.L., Flanders W.D., Long Q., Sidelnikov E., Fedirko V., et al. A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients. Cancer Research 2011, 71:413-423.
142. Fedirko V., Bostick R.M., Flanders W.D., Long Q., Shaukat A., Rutherford R.E., et al. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prevention Research (Phila) 2009, 213-223.
143. Wactawski-Wende J., Kotchen J.M., Anderson G.L., Assaf A.R., Brunner R.L., O'Sullivan M.J., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. New England Journal of Medicine 2006, 354:684-696.
144. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. American Journal of Clinical Nutrition 2007, 85:1586-1591.
145. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. British Medical Journal 2003, 326:469-472.
146. Ding E.L., Mehta S., Fawzi W.W., Giovannucci E.L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. International Journal of Cancer 2008, 122:1690-1694.
147. Thomas M.G. Luminal and humoral influences on human rectal epithelial cytokinetics. Annals of the Royal College of Surgeons of England 1995, 77:85-89.
148. Spina C., Tangpricha V., Yao M., Zhou W., Wolfe M.M., Maehr H., et al. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. Journal of Steroid Biochemistry and Molecular Biology 2005, 97:111-120.
149. Berger A.C., Sigurdson E.R., LeVoyer T., Hanlon A., Mayer R.J., Macdonald J.S., et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. Journal of Clinical Oncology 2005, 23:8706-8712.
150. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clinical Colorectal Cancer 2012, 11:1-13.
151. Gaschott T., Werz O., Steinmeyer A., Steinhilber D., Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochemical and Biophysical Research Communications 2001, 288:690-696.
152. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. Journal of Clinical Oncology 2010, 28:2777-2783.